Drug Profile
Sitagliptin/simvastatin
Alternative Names: Januvia/Zocor; Juvicor; Juvisync; MK-0431D; MK-431D; Tesozor; Xelezor; Zocor/JanuviaLatest Information Update: 04 Nov 2018
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antihyperglycaemics; Antihyperlipidaemics; Naphthalenes; Pyrazines; Triazoles
- Mechanism of Action CD26 antigen inhibitors; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Dyslipidaemias; Type 2 diabetes mellitus
Most Recent Events
- 24 Jun 2018 Biomarkers information updated
- 01 Aug 2017 Discontinued - Phase-III for Type-2 diabetes mellitus in Vietnam, Italy, Poland, Hungary, Latvia and Lithuania (PO), because not listed on Merck pipeline of August 2017
- 30 Apr 2015 No recent reports on development identified - Phase-III for Type-2 diabetes mellitus in Vietnam (PO)